סטאבניר

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

PRAVASTATIN SODIUM 40 MG

MAH:

BIOAVENIR LTD

ATC_code:

C10AA03

pharmaceutical_form:

TABLETS

administration_route:

PER OS

manufactured_by:

WEST PHARMA- PROD. DE ESPEC. FARMACEUT.S.A.

therapeutic_group:

PRAVASTATIN

therapeutic_indication:

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infa

authorization_date:

2013-05-01